|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nicolas Bralet and Megan Lan, MBA, MA, discuss how companies can de-risk their device selection as they bring this new generation of high-volume, high-viscosity biologics to market.
|
|
|
David Bunka, PhD, and Emily Robinson, PhD, focus on a new breed of affinity binders that can be used as an alternative to antibody therapeutics and has the potential to reshape the industry, delivering new medicines with improved safety and efficacy profiles and reduced healthcare costs.
|
|
|
Bob Wieden and Chun Wang, PhD, discuss how significant challenges, coupled with the complexity and diversity of new pharmaceuticals, have fueled the development of a novel polymeric drug delivery platform that overcomes a great many bioavailability and delivery obstacles.
|
|
|
Robert Davidson says there have been significant advances in clinical development of this novel drug delivery system, and the technology is rapidly moving from just a theory to practical real-world application.
|
|
|
|
|
|
|
|
|

Enteris BioPharma Inc., a wholly owned subsidiary of SWK Holdings Corp. (Nasdaq: SWKH), is a fully integrated development and manufacturing organization offering innovative oral drug delivery solutions. Since its founding in 2013, Enteris has adapted its oral drug delivery technology to advance multiple internal and client programs into the clinic. More recently, Enteris has completed a renovation of its 32,000 square-foot GMP facility, including HPAPI containment and handling, in Boonton, New Jersey, enabling long-term partnerships for challenging solid oral drug product development from preclinical through commercial cGMP manufacturing. Click her for more.
|
|
|
|
|
|
 |
|
Q-VANT Biosciences has launched as the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants including QS-21. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune….
|
|
 |
|
Ocugen, Inc.and its partner, Bharat Biotech recently announced results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of candidate vaccine….
|
|
 |
|
atai Life Sciences N.V. recently announced the US FDA has given Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R-ketamine). atai plans to initiate the….
|
|
 |
|
Sana Biotechnology, Inc., IASO Biotherapeutics, and Innovent Biologics recently announced the companies entered into an agreement pursuant to which Sana obtained from IASO Bio and Innovent non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct for use in certain….
|
|
 |
|
Malvern Panalytical recently announced its acquisition of Creoptix AG, a specialist bioanalysis sensor company. The acquisition forms a critical part of Malvern Panalytical’s strategy to….
|
|
|
|
|
Upcoming eNewsletter Features:
January 26 – Bioavailability
February 2 – Analytical Instrumentation
|
|
|
|
|
|
|
|